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People with cystic fibrosis (CF) typically have chronic lung infections, predominantly with Pseudomonas 
aeruginosa. Lung inflammation, in connection with bacterial colonization, is one of the major factors 
contributing to the morbidity and mortality of CF patients. Recent studies suggest that a common 
mutation among CF P. aeruginosa isolates (in the gene mucA) results in high-level expression of 
lipoproteins which stimulates a pro-inflammatory reaction in cultured CF-derived airways cell (CFBE). 
Our previous work in this area has revealed that a strain containing a mutation in the putative lipotoxin 
gene PA4326 is dramatically less toxic to CFBE. We hypothesize that lipotoxins lead to airway structure 
damage by causing epithelial cell death and tissue destruction, possibly as a downstream effect of immune 
stimulation. Our results demonstrate that deletion of the PA4326 gene does not affect growth, motility, 
adhesion, or biofilm development. However, this mutant strain produces 59.1% less pyocyanin compared 
to the non-mutant strain. Pyocyanin is a bacterial toxin that triggers airway inflammation by stimulating 
the immune system to produce the signaling molecule IL-8. Thus, our data suggest a possible clue about 
the decreased toxicity of the PA4325 mutant. The aim of future work is to confirm the role of this 
lipotoxin gene in the inflammatory process and to elucidate the underlying mechanism of its function. Our 
long term goal is to characterize other lipotoxins and to develop a novel inhibitor of lspA (a bacterial gene 
required for lipotoxin production) as an anti-inflammatory strategy to slow down the airway damage and 
hence improve the longevity and quality of life for people with CF. 
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